Skip to Content

Kitabis Pak Approval History

  • FDA approved: Yes (First approved December 2nd, 2014)
  • Brand name: Kitabis Pak
  • Generic name: tobramycin
  • Dosage form: Inhalation Solution
  • Company: PulmoFlow, Inc.
  • Treatment for: Cystic Fibrosis

Kitabis Pak (tobramycin) is an aminoglycoside inhalation solution co-packaged with a PARI LC PLUS® Reusable Nebulizer for the management of cystic fibrosis.

Development History and FDA Approval Process for Kitabis Pak

DateArticle
Dec  3, 2014Approval FDA Approves PulmoFlow's Kitabis Pak Tobramycin & Nebulizer Combination for Cystic Fibrosis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide